Document Detail


Febuxostat (Teijin/Ipsen/TAP).
MedLine Citation:
PMID:  16312139     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Febuxostat (TEI-6720; TMX-67), an oral non-purine, selective inhibitor of xanthine oxidase (NP-SIXO), is being developed by Teijin, with licensees Ipsen and TAP Holdings, for the potential treatment of gout. In February 2005, it was reported that launch in Japan was expected to be delayed for several years due to the need for additional clinical trials; in May 2005, an EU filing was expected by the end of 2005.
Authors:
Brian Tomlinson
Related Documents :
22433899 - Influence of chronic moderate sleep restriction and exercise on inflammation and carcin...
17241419 - Making scents: improvement of olfactory profile after botulinum toxin-a treatment in he...
22208549 - Assessing the influence of the built environment on physical activity for utility and r...
1554209 - Nasal cannula and transtracheal oxygen delivery. a comparison of patient response after...
3161669 - The effect of ipratropium bromide (atrovent) on the air conditioning capacity of the nose.
9562219 - Effect of a nasal dilatator on nasal patency during normal and forced nasal breathing.
11689749 - Rating of perceived exertion during high-intensity treadmill running.
11181599 - Substrate utilization during exercise with glucose and glucose plus fructose ingestion ...
1406169 - Exercise-induced bronchospasm in the young athlete: guidelines for routine screening an...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current opinion in investigational drugs (London, England : 2000)     Volume:  6     ISSN:  1472-4472     ISO Abbreviation:  Curr Opin Investig Drugs     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-11-29     Completed Date:  2006-06-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100965718     Medline TA:  Curr Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1168-78     Citation Subset:  IM    
Affiliation:
Division of Clinical Pharmacology, Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, SAR China. btomlinson@cuhk.edu.hk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Drug Evaluation, Preclinical
Enzyme Inhibitors / pharmacokinetics,  pharmacology,  therapeutic use*
Gout / drug therapy*
Humans
Patents as Topic
Randomized Controlled Trials as Topic
Structure-Activity Relationship
Thiazoles / pharmacokinetics,  pharmacology,  therapeutic use*
Xanthine Oxidase / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Thiazoles; 144060-53-7/febuxostat; EC 1.17.3.2/Xanthine Oxidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Potential immunosuppressive therapeutics to target small vessel vasculitis of the kidney.
Next Document:  Velafermin (CuraGen).